-
Kintor Pharma’s GT20029 Shows Positive Results in Phase I Study for Androgenetic Alopecia and Acne
•
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive results from a Phase I clinical study in China for its GT20029, which is being developed to treat androgenetic alopecia and acne. The study demonstrated that GT20029 has a good safety, tolerability, and pharmacokinetics profile. Study DetailsThe randomized, double-blind, placebo-controlled Phase…
-
FibroGen Sues Former Employees and Two Pharma Firms for Trade Secret Theft
•
US-based FibroGen Inc. has filed a lawsuit against two former employees, Liu Dong and Deng Shaojiang, accusing them of trade secret theft. The case, filed with the US District Court for the Northern District of California, also names two pharmaceutical firms as co-defendants: US-based Kind Pharmaceuticals LLC and China-based Hangzhou…
-
JS InnoPharm and Strategia Holdings Form JSI Ventures in Boston
•
Shanghai-based JS InnoPharm Ltd has announced an agreement with US firm Strategia Holdings LLC to establish JSI Ventures Inc. (JSV) in Boston, Massachusetts. The new venture aims to comprehensively integrate management teams and new drug research and development (R&D) projects from both companies. Dr. Keizo Koya, founder of Strategia, will…
-
Jianke.com Files for Hong Kong IPO with Focus on Chronic Disease Management
•
China-based smart healthcare service platform Jianke.com (Fangzhou Inc.) has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. Citibank, UBS, and ABC International will act as co-sponsors. The filing marks a significant step in the company’s expansion plans, aiming to leverage its comprehensive healthcare services and…
-
China’s First Gene Therapy for Deafness, RRG-003, Begins Clinical Study
•
RRG-003, an adeno-associated virus (AAV) gene therapy co-developed by China’s Shanghai Dingxin Gene Technology Co., Ltd and the Eye & ENT Hospital of Fudan University, has initiated a clinical study targeting hearing loss in the country. This marks the first gene therapy trial for deafness, with the first patient expected…
-
Shanghai Hosts Yangtze River Delta Alliance VBP Tender for 44 Drugs
•
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a document indicating that the city will host the Yangtze River Delta Alliance volume-based procurement (VBP) tender for 44 drugs on December 13, 2022. The tender involves drugs from Shanghai, Zhejiang, and Anhui provinces. The total procurement amount is estimated at around…
-
BeiGene to Present Final PFS Results for Brukinsa at ASH Meeting
•
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced plans to present the final progression-free survival (PFS) superiority analysis results of the Phase III ALPINE study for its Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) at the annual American Society of Hematology (ASH) meeting. The study assessed…
-
Kunshi Biotechnology and Puheng Technology Partner on 3D NAC-Organ Platform for CAR-Macrophage Screening
•
Kunshi Biotechnology (Shenzhen) Co., Ltd and Suzhou Puheng Technology Co., Ltd have entered into a strategic partnership to utilize a 3D NAC-Organ technology platform to establish a high-throughput in vitro screening system for CAR-Macrophage cells. The collaboration aims to enhance the research and development (R&D) of new immunotherapies targeting solid…
